Veeva Systems – AI Offensive and only 12% of the market penetrated! I see further potential

Veeva Systems (VEEV) impresses me with its relative strength: On November 5, the stock only fell by 0.17% while the Nasdaq dropped by 5.5%. The specialist in pharmaceutical and biotech software helps companies organize clinical trials, approvals, and drug distribution. During the subsequent Investor Day, Veeva raised its estimate of the addressable market supported by AI from $20 billion to over $30 billion. Based on the expected annual revenue, Veeva currently covers only about 12% of this market volume. What I find particularly exciting is that...